ITL News & Reports
Are you looking for Annual and Financial Reports? Click here...
Date
Title
Pages
Download
Price Sensitive
Appendix 4D with financial statements, six months ended 31 December 2010.
ITL has released it Annual Report for the 2008-2009 business year.
2009 Shareholders Letter, Notice of Meeting and proxy form, Explanatory Memorandum
The ITL Limited Audit and Risk Management Committee has been formed by the Board of Directors to act on behalf of the Board in overseeing all material aspects of the company’s financial reporting, con
Further to the publication of ITL Limited's half yearly results in which a number of restructuring initiatives were announced, the Board and Executive are please to provide this update of company perf
Price Sensitive
Appendix 4D with financial statements, six months ended 31 December 2008.
After an extensive search the Directors of ITL Limited are pleased to announce the appointment of Mr Brian Andrews as Chief Executive Office of the ITL Group, effective January 5th 2009.
The ITL Board has today accepted the resignation of CEO Mr Bill Mobbs. Mr Mobbs has also retired as a director of the company.
ITL Healthcare SEA has been awarded the 2008 Malaysia Medical Device Distributor of the Year at the Frost & Sullivan Excellence in Healthcare Awards ceremony in Singapore
The 3 years extensions are with: Terumo Penpol - India; Terumo Corporation - Japan; and Terumo Medical Products - China
Appendix 3Y - Change of Director’s Interest Notice
The Directors of ITL are pleased to announce the execution of agreements to acquire the businesses of two Malaysian companies - Inspire Vision Technologies Sdn. Bhd. and Inspire Vision Medical Sdn. Bh
American Red Cross Extends Contract for further two years
Price Sensitive
Results for announcement to the market, Supplementary Appendix 4D information, Half yearly report.
ITL Healthcare, a member of the ITL Group, today made announcement about its new ethylene oxide steriliser is now in commercial operation.
ITL Healthcare Pty Ltd, a member of ITL Group, is pleased to announce it has signed a two year non-exclusive, preferred supplier agreement with Ramsay Health Care Australia Pty Ltd to provide custom p
Bill Mobbs Directors Notice of Interest Change
Julian Gosse Directors Notice of Interest Change
Richard England Directors Notice of Interest Change
Roy Rose Directors Notice of Interest Change
New issue announcement, application for quotation of additional securities and agreement.
ITL Change of record date for Final Dividend
Company Snapshot ITL Limited (ASX:ITD) 23rd August 2007
Price Sensitive
Appendix 4E: Preliminary final report for the year ended 30 June 2007
Price Sensitive
The Company confirms the forecasted revenue, net profit and EBITDA performance as previously advised in the 6 June 2007 market update.
ITL aITL announces that it has raised $8.32M by way of a placement of 16 million shares at 52c. The placement brings several leading fund managers onto the ITL register.
Medical device and kit manufacturer ITL has raised $8.32 million to fund its Asian growth strategy.
ITL Limited confirms the interim dividend of $0.005 per share.
ITLs R and D TINA Project has been boosted by additional grant funds from the Commonwealth Government R and D Start Programme
Price Sensitive
Appendix 4D with financial statements - dividend payable.
ITL and Fresenius HemoCare have entered into a cooperation agreement to trial ITLs two new retractable safety needles.
ITL Group Limited HY07 Guidance of NPBT $2.1m, EBITDA 2.9m
ITL Advises Market that the un-audited Revenue for the first half to 31st Dec 06 was $20.3M
Appendix 3Y Directors Interest Notice
Appendix 3Y Directors Interest Notice
ITL (ASX:ITD), has received the US Court of Appeals decision on the long running ‘Platypus’ patent infringement case between DSU Medical Corporation Vs ITL & JMS (ITL’s US Distributor).
ITL (ASX:ITD) is proud to announce that it has gained TGA approval for its new Australian based manufacturing facility at Chelsea Heights, Melbourne.
Appendix 3Y Directors Interest Notice
Appendix 3Y Directors Interest Notice
Appendix 3Y - Change of Directors Interest
FY 07 Guidance of 15% Revenue Growth to $36m
Price Sensitive
ITL Confirms 2006 Record Profit as Revenue Continues to Grow
674,259 ordinary shares have been taken up by ITL Directors under the Dividend Reinvestment Plan
CEO Mr Bill Mobbs and non Executive Director Mr Roy Rose have both lodged Appendix 3Y Notices.
ITL reported to the ASX today that it has no outstanding options.
ITL Limited confirms that the final dividend of $0.01 per share was declared an eligible dividend under the Dividend Reinvestment Plan (DRP) and gives notice that the subscription price for DRP Shares
Bill Mobb's presents an investor update to Boardroom Radio.
ITL Annual General Meeting supporting Documentation
ITL has just released our Annual Report for Financial year 2005/06
New issue announcement, application for quotation of additional securities and agreement
ITL (ASX: ITD, www.itl-limited.com) specialises in creating medical devices and procedure kits for global healthcare markets.
Report on ITL's performance in 2006 and summary of business for investors.
Price Sensitive
ITL is pleased to announce a five year supply agreement with bioMérieux for ITL's new SampLok® Blood Collection Adapter for use with the BacT/ALERT® product line.
Important figures for 2006, presented by Bill Mobbs, CEO.
Price Sensitive
Appendix 4E and preliminary Full Year Financial Report
Please find attached our July edition of the ITL Newsletter.
Form 604, has been lodged with the stock exchange today.
Price Sensitive
ITL wishes to advise the market of an updated guidance for our 2006 financial results.
Blips on the radar that could make it big” The review written by Trevor Hoey says “ its full-year impact along with management’s forecast of organic growth of 20 per cent should mak
Price Sensitive
Intersuisse’s recommendation is: “The Company is forecast to experience strong sales growth. It generated its first profit on December 2005, we anticipate a NPAT of $2.8m for the fiscal year 2006.
InterFinancial Review of ITL and Interview with ITL's CEO Bill Mobbs
ITL has signed a $6 million (AUD) contract to supply medical equipment to the prestigious Prince Court Medical Centre (PCMC) in Malaysia.
Director Mr Roy Rose has purchased 100.000 ordinary ITL shares
ITL was invited to present at the Citigroup Micro Caps Conference held in Sydney on Tuesday 4 April 2006. This was a great opportunity to showcase our company to over 100 business analysts and invest
ITL has just released the March 2006 version of our Newsletter.
ITL CFO Susan Williams has purchased 500,000 ordinary shares, issued on 13 March 2006
The Australian Financial Review wrote today that ITL is one of the top 10 undervalued stocks. Reporter Trevor Hoey said that ITL was a ‘small firm with big potential.’ ITL was nominated by MMC Asset
ITL is again showing a strong result on the back of consistant growth.
Price Sensitive
ITL has just released its Appendix 4D Half Yearly Results - February 2006
Price Sensitive
Half-yearly report six months ended 31 December 2005
Price Sensitive
New issue announcement, application for quotation of additional securities and agreement
ITL wishes to advise the market that our revenues for the first half to 31st December 2005 were $13.3M this is a 20% increase over the first half of 2004/05 revenues of $11.1M.
ITL today announces it has completed the acquisition of leading Malaysian healthcare company, Heal Marketing Sdn Bhd.
Change of Director's Interest Notice: Julian Gosse
Change of Director's Interest Notice: Roy Rose
Price Sensitive
Key points of analysis, interview with Bill Mobbs CEO
In an encouraging start to the 05/06 financial year, ITL has increased its first quarter revenue by 26% when compared with the corresponding period last year.
We advise that the outcome of voting at ITL’s AGM on 27 October 2005 was as follows:
Price Sensitive
ITL has extended its long term relationship with the world’s largest blood banking organisation, the American Red Cross (ARC), for the supply of ITL’s range of patented safety and ergonomic blood coll
Price Sensitive
Notice of Change of Interest of Substantial Holder - Dr Jagmohanbir Dillon has lodged Form 604
Mailing to Shareholders for ITL AGM 2005
Appendix 3B - New issue announcement, application for quotation of additional securities and agreement
Initial Director's Interest notice: Roy Rose
ITL is pleased to announce the appointment of Mr Roy Rose to the Board as a non- executive Director from the 1st of September 2005.
ITL is pleased to advise the full year results are stronger than the forecast, released in February 2005.
Price Sensitive
Full Year Report 12 Month Ended 30 June 2005
ITL is proud to announce that our Malaysian manufacturing facility has gained certification to the Environmental Management System ISO 14001:2004 and has also successfully upgraded our Quality Managem
Equity Capital Markets Limited press release on ITL's 2004-2005 performance and forecast.
ITL is pleased to advise that the un-audited second half results are stronger than the second half outlook, released in February 2005.
Price Sensitive
ITL wishes to advise the market of an updated guidance for our 2006 financial results.
Julian Gosse - Change of Director's Interest Notice
Macquarie Financial Services retains an Outperform recommendation on ITL.
ITL is pleased to release information about the Company’s recent performance. ITL is tracking in line with forecasts (issued February 2005) for the second half of financial year 04/05
Price Sensitive
ITL has signed a $6 million (AUD) contract to supply medical equipment to the prestigious Prince Court Medical Centre (PCMC) in Malaysia.
Price Sensitive
ITL has signed a $6 million (AUD) contract to supply medical equipment to the prestigious Prince Charles Medical Centre (PCMC) in Malaysia.
Bill Mobbs - Change of Director's Interest Notice
ITL was invited to present at the Citigroup Micro Caps Conference held in Sydney on Tuesday 4 April 2006. This was a great opportunity to showcase our company to over 100 business analysts and invest
Change of Director's Interest Notice - Richard England
Change of Director's Interest Notice - Julian Gosse
Price Sensitive
ITL CFO Susan Williams purchased 500,000 ordinary shares issued on 13 March 2006.
Changes to Bill Mobbs' company holdings.
Changes to Julian Gosse's company holdings.
The Australian Financial Review wrote today that ITL is one of the top 10 undervalued stocks. Reporter Trevor Hoey said that ITL was a ‘small firm with big potential.’ ITL was nominated by MMC Asset
Price Sensitive
Half-yearly report - Six months ended 31 December 2004
ITL's Managing Director, Mr Bill Mobbs presented this PowerPoint presentation as a summary of ITL's first year as a public company and announced the way forward. Significant changes, review of current
Price Sensitive
Chairman’s address for Annual General Meeting, Tuesday, 30th November 2004, Canberra
We advise that the outcome of voting at ITL’s AGM on 30 November 2004 was as follows
Price Sensitive
ITL has resolved its pending patent/licensing dispute with Fresenius/NPBI.
Price Sensitive
ITL has recently signed a major new contract with Australia’s largest private hospital operator, Affinity Health (formerly Mayne Health).
Bill Mobbs - Change of Director’s Interest Notice
Richard England - Change of Director’s Interest Notice
The ITL AGM proxy form can be downloaded as a pdf and mailed or faxed to ITL.
ITL has announced the 2004 Annual General Meeting. The meeting is scheduled for November 30 and will
ITL UK sales director David Laffar addresses the directors of the Russian and CIS blood service.
ITL Limited advises that 49,614,000 shares are today released from voluntary escrow.
Equity Capital Markets Limited: ITL Limited Management Restructuring
Joint managing director and co-founder of ITL, Dr Jag Dillon announced his resignation at the last I
Macquarie Financial Services: ITL Limited Management Changes
ITL Limited releases its first annual report. ITL Limited was first listed on the ASX in October of
ITL has accepted a $2.4 million dollar grant from the Federal government to develop next generation needle technology that will reduce the risk of needle stick injuries.
Older ITL announcements can be downloaded from the ASX website.